Jasper Therapeutics is being renewed through a merger with Kira Pharmaceuticals, a move designed to stabilize the company after setbacks that reduced its market value and reshaped its clinical posture. The transaction includes a concurrent licensing deal with startup Mirador, according to coverage of the agreement. For Jasper, the combined entity’s pipeline centers on complement-targeting programs, including KP-104 (v vensobafusp alfa), a dual complement inhibitor in nephrology indications and paroxysmal nocturnal hemoglobinuria. Jasper also disclosed planned next steps with regulatory discussions around clinical development. Financially, the merger will be supported by a $132 million private placement, positioning the company to fund continued exploration of its remaining antibody programs and accelerate planned data readouts. The deal also highlights how complement biology continues to attract restructuring capital when individual assets face execution risk.